{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-23-059159","form_type":"8-K","ticker":"BMY","cik":"0000014272","company_name":"BRISTOL MYERS SQUIBB CO","filed_at":"2023-12-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.038405+00:00","generated_at":"2026-06-07T07:49:00.717399+00:00","sec_items":["8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":1.0,"calibrated_materiality_score":1.0,"confidence":"high","headline":"Bristol Myers Squibb to acquire Karuna Therapeutics for $330/share, ~$14B equity value","bullets":["Deal valued at $14.0B equity / $12.7B net of cash; 53.4% premium to KRTX Dec 21 close.","Karuna's lead asset KarXT for schizophrenia; PDUFA date Sept 26, 2024; also in trials for Alzheimer's psychosis.","Expected to close H1 2024, subject to Karuna shareholder and regulatory approvals; financed with new debt.","Non-GAAP EPS dilutive by ~$0.30 in 2024 due to financing cost; BMS cites portfolio prioritization to offset."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-23-059159","json":"https://secwatch.observer/filing/0001140361-23-059159.json","markdown":"https://secwatch.observer/filing/0001140361-23-059159.md","text":"https://secwatch.observer/filing/0001140361-23-059159.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/14272/000114036123059159/0001140361-23-059159-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/14272/000114036123059159/ef20017313_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T07:49:00.717399+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}